Cutaneous squamous cell carcinoma (CSCC) is the second most common type of skin cancer. For patients with advanced CSCC, treatment with immune checkpoint inhibitors such as cemiplimab and pembrolizumab has improved outcomes significantly. Hence, identifying patients at high risk of progression is critical to provide for optimal outcomes. Please join our expert dermatology and oncology faculty along with CSCC patients and an oncology social worker as they discuss the patients journey of care and the latest clinical evidence in the multidisciplinary management of advanced CSCC.
- Provider:Haymarket Medical Education
- Activity Link: https://www.mycme.com/courses/immune-checkpoint-inhibitor-therapy-for-advanced-cscc-9297
- Start Date: 2024-02-08 06:00:00
- End Date: 2024-02-08 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: Source: Regeneron Pharmaceuticals, Inc. - Amount: 349905.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest